Can Customer Reviews Get a Peptide Store in Trouble?

Yes, in our judgment, customer reviews can get a peptide store in trouble: FDA has quoted customer reviews or testimonials from sellers' own websites as evidence of intended use in 3 warning letters we read, from 2019, 2022 and 2025 [2][3][4]. In its August 2019 letter to Let's Talk Health, FDA called the quoted entries reviews the company "reviewed and selected for posting" on its website [2].

Research only labeling did not stop FDA from finding drug intended use in website evidence in its August 2026 letters to two peptide sellers. [5][6] The FTC adds a second exposure: its consumer review rule, published in August 2024, makes review misconduct a rule violation, and the FTC's current penalty table sets the maximum for a rule violation at $53,088 per violation. [8][13][15] Our working rule: treat every review your store displays as if it were copy you published.

This guide is for founders and operators of research peptide stores. When you finish it, you will have three things you can hand to a payment reviewer or to your lawyer: a list of every place customer text appears on your store, a written review policy you can copy and publish, and a moderation log that shows the policy was applied to every rating. The sections in between explain why each one matters, from what FDA, the FTC, payment processors and Google have each said about customer written text. Every quotation is copied from the primary source and cited to its section, page or paragraph. It is not legal advice.

Discuss your store review setup: book my call

Key Facts

• FDA's intended use regulation, 21 CFR 201.128, says intent can be shown by labeling claims, advertising matter, and written statements by the responsible persons "or their representatives." [1]
• In its August 2021 final rule, FDA wrote that it "may look to any relevant source of evidence, including a variety of direct and circumstantial evidence" (86 FR 41383, at 41388). [12]
• In an August 2019 warning letter, FDA listed customer reviews from the company's website and said the company had "reviewed and selected" them for posting. [2]
• In a November 2022 letter, FDA quoted testimonials from a "CBDFX VERIFIED PRODUCT REVIEWS" page that the seller's own copy linked to with the words "customer reviews." [3]
• In a June 2025 letter, FDA quoted reviews it labeled as taken from the "Customer Reviews section" of product pages. [4]
• The August 2026 letters to NuScience Peptides and Peptide Partners say website evidence established intended use despite labeling statements limiting the products to research use. [5][6]
• FDA's own manual calls a warning letter "informal and advisory," and says FDA "is under no legal obligation to warn" a firm before enforcement action outside a few defined areas (FDA Regulatory Procedures Manual, ch. 4, sec. 4-1-1, pp. 3 to 4, July 2024). [14]
• The FTC's Endorsement Guides say "Consumer endorsements themselves are not competent and reliable scientific evidence" (16 CFR 255.2(a)). [7]
• The FTC's consumer review rule bans buying reviews of a particular sentiment, undisclosed insider reviews and suppression of displayed reviews based on rating or negative sentiment (16 CFR 465.4, 465.5 and 465.7). [8]
• Stripe lists businesses that "use deceptive testimonials" or "use fake testimonials" among the businesses that must not use its services. [10]
• Google says a business that controls the reviews about itself is ineligible for star review snippets on LocalBusiness or Organization pages. [18]

TL;DR

• FDA has quoted reviews from sellers' own product pages and review pages, and a testimonial from a brochure shipped in the box, back to them in warning letters. [2][3][4]
• A disclaimer did not protect one seller. It wrote that it could not make claims, then linked to a reviews page, and FDA quoted testimonials from that page. [3]
• The FTC's guides treat a disclaimer that testimonials "do not prove our product works" as likely ineffective when the page is built on testimonials. [7]
• Review apps, Q&A widgets, photo galleries, package inserts, social profiles and structured data all put customer text on your store. Our working rule is to treat all of it as yours.
• In our reading, you can moderate, but the rule must be about content, applied to every review, and never about whether the review is positive or negative. [8]
• A rule violation under the FTC review rule can cost up to $53,088 per violation, though the FTC itself says courts may set much lower amounts. [13][15]
• Our recommendation: write a review policy before you turn on a review app, not after a letter or a payment hold.

Why does FDA treat a customer's words as your claim?

In our reading, FDA can treat displayed customer words as yours because it decides what a product is by its intended use, and its regulation says that intent is objective and can be shown by more than the seller's own labeling. [1] The question is never only what the seller wrote. It is what the whole record shows the product is for.

The starting point is the statute. The Federal Food, Drug, and Cosmetic Act defines drugs to include "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" and "articles (other than food) intended to affect the structure or any function of the body of man or other animals" (21 U.S.C. 321(g)(1)(B) and (C)). [16] In our reading, the key word in both clauses is "intended." A vial of the same powder can sit inside or outside the drug definition depending on what the seller is shown to intend.

FDA's regulation then says how intent is shown. Intent "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," including labeling claims, advertising matter, and written statements by the responsible persons "or their representatives" (21 CFR 201.128). [1] Notice what is missing, in our reading: the regulation does not limit evidence to text the seller wrote itself.

What the 2021 intended use rule added

In August 2021, FDA amended 201.128 and answered a comment arguing that intended use is limited to the seller's own promotional claims. FDA's response began: "We disagree" (86 FR 41383, at 41386, 2 August 2021). [12] It went on to write that it "has steadfastly maintained for decades that, in determining a product's intended use, the Agency may look to any relevant source of evidence, including a variety of direct and circumstantial evidence" (86 FR at 41388). [12]

The economic analysis of the same rule restates the point: the rule "clarifies FDA's longstanding position that the intended use of a drug or device product can be based on any relevant source of evidence" (86 FR at 41399). [12]

The 2021 rule did carve out one narrow case. A firm "would not be regarded as intending an unapproved new use for an approved drug based solely on that firm's knowledge that such drug was being prescribed or used by health care providers for such use" (21 CFR 201.128, as printed at 86 FR 41401). [1][12] Our reading, which is judgment: that carve out is about approved drugs and prescribers, and it protects knowledge alone. The 2026 peptide letters treat the products as unapproved new drugs, and nothing in the carve out describes a seller that chooses to display customer text on its own product page. [5][6]

The amended text also speaks to resellers. When a packer, distributor or seller intends an article for different uses than its supplier did, that party "is required to supply adequate labeling in accordance with the new intended uses" (86 FR at 41401). [12] Our reading: a store that relabels or resells a supplier's product owns the intended use its own pages create, including the reviews it displays.

Why displayed reviews look like your expression

A customer is not your employee. Our reading, which is judgment and not a legal ruling: once you choose to display a customer's words on a product page, they sit next to your product, under your brand, on a page a regulator reads as a whole. The phrase "circumstances surrounding the distribution of the article" in 201.128 is broad enough, in our reading, to take in what the store chose to publish beside the product. [1]

The letters below fit that reading: FDA did not stop at the copy the seller wrote. It quoted the customer text the seller put on the page. [2][3][4] In our view, this matters more for a research peptide store than for most categories, because the store's position rests on the product being sold for laboratory research, not for use in people. A single displayed review that describes personal use can work against that position on the same page that states it.

What is an FDA warning letter, and what happens after one?

A warning letter is FDA's notice that it sees a violation of regulatory significance; it is not a court ruling, but it is not a formality either. FDA's Regulatory Procedures Manual says "Warning Letters are issued only for violations of regulatory significance" (RPM ch. 4, sec. 4-1-1, p. 3, MAN-000007 Rev. 12, July 2024). [14]

The same section calls the letter "the agency's principal means of achieving prompt voluntary compliance with the Federal Food, Drug, and Cosmetic Act (the Act)" (p. 3). [14] It then sets the limits of what the letter means: "A Warning Letter is informal and advisory. It communicates the agency's position on a matter, but it does not commit FDA to taking enforcement action" (p. 4). [14] And the manual adds that "FDA does not consider Warning Letters to be final agency action on which it can be sued" (p. 4). [14]

Two lines in the manual matter most to an operator who has never received a letter. First, "FDA is under no legal obligation to warn individuals or firms that they or their products are in violation of the law before taking enforcement action, except in a few specifically defined areas" (p. 3). [14] Second, "responsible individuals should not assume that they would receive a Warning Letter, or other prior notice, before FDA initiates enforcement action" (p. 3). [14]

The manual lists what that enforcement can look like: "sequential or concurrent FDA enforcement actions such as recall, seizure, injunction, administrative detention, civil money penalties and/or prosecution" (p. 3). [14] Our reading: a store should not wait for a letter to clean up its reviews, because the letter is not a guaranteed first step.

What the letters ask the recipient to do

The letters themselves set short clocks. The 2025 Hydroxie letter asked the company to "notify FDA in writing, within 15 working days of receipt of this letter." [4] Both August 2026 peptide letters ask for a written response "within fifteen (15) business days of receipt of this letter." [5][6]

The letters also say they are not complete lists. The 2026 peptide letters state: "This is not intended to be an all-inclusive list" of violations, and the Hydroxie letter says it "is not intended to be an all-inclusive statement of violations." [4][5][6] They also name the next step. The Hydroxie letter warns that "Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction," and the 2026 peptide letters warn of "regulatory or legal action without further notice including, without limitation, seizure and injunction." [4][5][6]

For an operator, our reading is that a letter that quotes product copy does not clear the reviews section, and a letter that quotes reviews does not clear the product copy. Each letter lists examples, not everything FDA saw.

What have FDA warning letters said about customer reviews?

Three FDA warning letters we read quoted customer reviews or testimonials from the seller's own site as evidence of intended use: Let's Talk Health (August 2019), CBDFX (November 2022) and Hydroxie (June 2025). [2][3][4] None of the three went to a peptide seller. Both 2026 peptide letters define intended use by citing 21 CFR 201.128, the regulation quoted above. [1][5][6] We describe each letter's handling of customer text below. We do not repeat the health claims inside the quoted reviews, because the point for an operator is where FDA found the text, not what it said.

Let's Talk Health, Inc. (August 6, 2019)

FDA's letter says it reviewed "your website and blog." [2] Under several products, FDA wrote: "Your website includes the following customer reviews, which you reviewed and selected for posting on your website," and then quoted them. [2] The letter also notes that the blog links "directly to and from your website." [2]

The letter also reached past the website. FDA wrote that the brochure enclosed with shipped products "contains evidence of intended use in the form of a personal testimonial." [2] That is customer text printed on paper and placed in the box, not a review widget.

What an operator should take from it, in our judgment: the phrase that matters is "reviewed and selected." Moderating reviews can make the published set look even more like your own selection. Customer text, in our reading, also does not need to be online to count. A testimonial in the shipping box was cited in the same letter as the website reviews. [2]

Newhere Inc. dba CBDFX (November 16, 2022)

FDA reviewed the company's website and its social media accounts on Facebook, Instagram, YouTube and Twitter, which the letter says "direct consumers to your website cbdfx.com to purchase your products." [3] The letter then says the website "contains evidence of intended use in the form of personal testimonials." [3]

The most instructive example sits on the company's "What is CBD" page. The seller's copy said it could not make claims "(as instructed by the FDA)," then pointed readers to customer reviews, with "customer reviews" linked to a page titled "CBDFX VERIFIED PRODUCT REVIEWS." FDA quoted testimonials from that page in the letter. [3] In that letter, the disclaimer did not stop FDA from quoting testimonials on the page it pointed to.

The same letter also cited a blog article that pointed to "anecdotal evidence," with that phrase linked to an article containing a testimonial. [3] Our reading: a blog post that quotes or links a customer's story is customer text on your domain, the same as a review widget.

Hydroxie, LLC (June 25, 2025)

FDA reviewed the company's website and its Instagram account, noting that "Your Instagram social media account directs consumers to your https://shop.hydroxie.com website." [4] FDA wrote that the website "contains evidence of intended use in the form of personal testimonials," and labeled the quoted examples as coming from the "Customer Reviews section" of named product pages. [4]

These were entries from the product pages' own Customer Reviews sections, the default review area most store themes create. [4] Of the three letters, this is the closest match to a typical review app setup on a modern storefront.

The pattern across all three

Read together, the three letters show FDA citing customer text from five kinds of places: product page review sections, a standalone reviews page, blog articles, social accounts that send buyers to the store, and a printed brochure in the box. [2][3][4] That is our tally from the letters we read, not FDA's own list.

The two August 2026 peptide letters we read cite evidence from the sellers' websites and labeling. They do not quote customer reviews. [5][6] That is a fact about two letters, not a promise about the next one. Check the FDA warning letter tracker for newer letters, and read what FDA warning letters say about peptide marketing for the copy those letters cite.

Does a research use only label protect the reviews section?

Our reading is no: in its two August 2026 peptide letters, FDA found drug intended use from website evidence despite labeling that limited the products to research use. [5][6] Both letters carry the finding in footnote 1.

In the NuScience Peptides letter, footnote 1 reads in part: "Despite statements on your product labeling marketing your products 'for laboratory, research, and analytical use' and 'not intended for human or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." [5] The Peptide Partners letter uses the same structure with its own labels, "for research use only" and "not for human or veterinary use." [6] The NuScience letter also frames its examples as coming "from your product labeling, including on your website," and defines intended use by citing 21 CFR 201.128. [5]

The letters list nine products (NuScience) and seven products (Peptide Partners), call them new drugs under section 201(p) of the FD&C Act because they are not generally recognized as safe and effective, and cite sections 505(a) and 301(d). [5][6] Neither letter needed a customer review to get there. Our judgment: if website copy alone was enough to outweigh a research use only label, a five star review that describes personal results adds evidence on the same side, not the other.

The FTC has said something similar about disclaimers

The FTC's Endorsement Guides reach a parallel conclusion about disclaimers next to testimonials. In an example about an advertiser whose page is built on customer testimonials, the Guides say that even with a disclaimer such as "Notice: These testimonials do not prove our product works. You should not expect to have similar results," the ad is "likely to be deceptive" unless the advertiser can substantiate the results the page conveys (16 CFR 255.2(e)(1)(ii)). [7]

The Guides add that the FTC tested the disclosure "Results not typical" and a stronger version, and found that "Neither disclosure adequately reduced the communication that the experiences depicted are generally representative" (16 CFR 255.2(e)(2)). [7] We read the same logic as applying to a "research use only" line beside a review that describes personal results (judgment). The label and the review are both on the page, and two different regulators have written that a disclaimer does not erase what the rest of the page says. [5][7]

What do the FTC's Endorsement Guides say about reviews you display?

In our reading, the Endorsement Guides treat a displayed customer review as your advertising whenever consumers are likely to read it as someone else's experience with your product. An "endorsement" means "any advertising, marketing, or promotional message for a product that consumers are likely to believe reflects the opinions, beliefs, findings, or experiences of a party other than the sponsoring advertiser" (16 CFR 255.0(b)). [7] The Guides say they "provide the basis for voluntary compliance with the law," and that "Practices inconsistent with these Guides may result in corrective action by the Commission under section 5" of the FTC Act (255.0(a)). [7]

The Guides also show how an excerpt changes character. In 255.0 Example 1, a film critic's review excerpted in the producer's advertisement "becomes an endorsement." [7] Our reading: a customer's review that a store pulls into its product page, a banner or an email works the same way.

Four rules in the Guides map directly onto a store's reviews section.

1. An endorsement cannot say what you could not say. "An endorsement may not convey any express or implied representation that would be deceptive if made directly by the advertiser" (255.1(a)). [7] Our reading: a review that describes personal results makes a claim your own copy is barred from making.

2. You are liable for what endorsements say. "Advertisers are subject to liability for misleading or unsubstantiated statements made through endorsements," and "An advertiser may be liable for a deceptive endorsement even when the endorser is not liable" (255.1(d)). [7]

3. Reviews are not proof. "Consumer endorsements themselves are not competent and reliable scientific evidence" (255.2(a)). [7] And an endorsement about a central attribute of a product is read as representative of what buyers will get (255.2(b)). [7]

4. Moderation cannot distort the picture. When they procure, suppress, boost, organize, publish or edit consumer reviews, "advertisers should not take actions that have the effect of distorting or otherwise misrepresenting what consumers think of their products," and that holds "regardless of whether the reviews are considered endorsements under the Guides" (255.2(d)). [7]

Section 255.1(b) adds that endorsements may not be "presented out of context or reworded so as to distort" what the endorser meant. [7] Section 255.1(f) names "review brokers, reputation management companies" among the parties that may be liable for their role in deceptive endorsements. [7] Our reading: an agency or app that curates reviews for you does not take the exposure off your store.

What the Guides tell advertisers to do

Section 255.1(d) does not stop at liability. It says advertisers should provide guidance to their endorsers, then lists "Monitor their endorsers' compliance" and "Take action sufficient to remedy non-compliance." [7] The same paragraph adds: "While not a safe harbor, good faith and effective guidance, monitoring, and remedial action should reduce the incidence of deceptive claims." [7] That sentence is about endorsers a business engages, but in our reading it describes the posture a store should take toward its review program as a whole: written guidance, monitoring, and a record of what was removed.

Two examples that fit review apps

The Guides include an example about forwarding reviews: "If it forwards only favorable reviews or omits unfavorable reviews, it is engaging in a misleading practice" (255.2(e)(4)(vii)). [7] Our reading: a review syndication setting that pushes only four and five star reviews to other sites fits that description.

Another example covers staff. In 255.5 Example 8, an employee who posts about the employer's product must disclose the relationship, and the Guides say "The disclosure requirements in this example would apply equally to employees posting their own reviews of the product on retail websites or review platforms." [7] For a small peptide store, our reading is that this reaches the founder's staff and contractors, and the FTC's review rule (below) adds relatives in some cases. [8]

The statute behind the Guides

In our reading, the FTC Act also makes false advertising for drugs a separate violation. "It shall be unlawful for any person, partnership, or corporation to disseminate, or cause to be disseminated, any false advertisement" for the purpose of inducing purchases of covered products (15 U.S.C. 52(a)). [17]

The FTC Act's own definition of "drug" in 15 U.S.C. 55(c) uses the same language as the FD&C Act, covering "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals." [17] Our reading: the same word, "intended," that drives FDA's analysis also appears in the FTC's.

What does the FTC's consumer review rule prohibit?

The FTC's Trade Regulation Rule on the Use of Consumer Reviews and Testimonials, 16 CFR Part 465, turns several review practices into rule violations. The FTC published it on 22 August 2024 (89 FR 68034, FR Doc. 2024-18519). [13] In the preamble the FTC explained that "the rule will enable the Commission to seek civil penalties against violators" (89 FR at 68037). [13] The Endorsement Guides, by contrast, are guidance: they "provide the basis for voluntary compliance with the law" (16 CFR 255.0(a)). [7]

The rule's definition of a consumer review includes star ratings with no text at all (16 CFR 465.1(d)). [8] A bare five star rating with no words is a consumer review under the rule. Its definition of purchasing a review covers giving "money, gift certificates, products, services, discounts, coupons, contest entries, or another review" (465.1(m)). [8]

Here is what each operative section covers, in our summary of the rule text. [8]

• 465.2, fake or false reviews and testimonials. A business may not write or create fake reviews, may not buy them, and may not disseminate fake testimonials it "knew or should have known" were false. It also may not procure reviews from its officers, managers, employees or agents for posting on third party sites in the cases the section describes. [8]
• 465.2(d), the review request exception. Paragraphs (b) and (c) do not apply to reviews that come from "generalized solicitations to purchasers," or to a business "merely engaging in consumer review hosting." [8] The preamble says these paragraphs "do not apply to mere consumer review hosting, even if the business prompts review submissions or aggregates star ratings" (89 FR at 68052). [13]
• 465.4, buying reviews of a set sentiment. A business may not "provide compensation or other incentives in exchange for, or conditioned expressly or by implication on, the writing or creation of consumer reviews expressing a particular sentiment, whether positive or negative." [8]
• 465.5, insider reviews. Officers and managers may not post undisclosed reviews about their own business, and may not solicit undisclosed reviews from relatives or employees under the conditions the section lists. [8]
• 465.6, company controlled review sites. A business may not present a website or entity it controls as an independent source of reviews. [8]
• 465.7, review suppression. No one may use unfounded legal threats, intimidation or false accusations to stop a review from being posted or to have it taken down, and a business may not misrepresent its displayed reviews as the full picture while suppressing reviews based on their rating or negative sentiment. [8]
• 465.8, fake social media indicators. A business may not buy or sell fake followers, views or similar indicators for a commercial purpose. [8]

What the FTC's preamble says about moderation

The preamble to the final rule explains how the FTC reads moderation. In footnote 252 it wrote that "Prompting the submission of consumer reviews that must be positive in order to obtain an incentive could violate Sec. 465.4," and that "Moderation of consumer reviews that results in the suppression of some of them based upon their ratings or their negative sentiment could violate Sec. 465.7(b)" (89 FR 68034, at 68052). [13]

The preamble also explains why the FTC thinks suppression is common. It found suppression prevalent based in part on "what it learned in another investigation about more than 4,500 merchants that were automatically publishing only 4- or 5-star consumer reviews" (89 FR at 68037). [13] Later it named the vendor: "more than 4,500 Yotpo merchant clients were automatically publishing only 4- or 5-star reviews and that most 1-star reviews and 2-star reviews submitted to those merchants were suppressed" (89 FR at 68064). [13] Our reading: an auto publish setting that only releases four and five star reviews is exactly the configuration the FTC described.

The FTC also kept 465.7(b) focused on the reviews section of a site. Section 465.7(b) covers "a portion of a website or platform dedicated in whole or in part to receiving and displaying consumer reviews," and the preamble says "The Commission did not intend for proposed Sec. 465.7(b) to cover the use of consumer reviews in marketing materials" (89 FR at 68065). [8][13]

In the same discussion (89 FR at 68065), the FTC added that "the use of non-representative consumer reviews in marketing could be deceptive in violation of section 5 of the FTC Act," and, in footnote 436, that "The rule does not prohibit such ``highlighting'' of specific reviews or testimonials, but the creation of a safe harbor for such highlighting is beyond the scope of the rule." [13]

What can a review rule violation cost?

Up to $53,088 per violation, per the FTC's current inflation adjusted table, though the FTC itself says courts may impose much lower amounts. The table lists "Section 5(m)(1)(A) of the FTC Act, 15 U.S.C. 45(m)(1)(A)" at $53,088, and says the amounts "apply only to penalties assessed after January 17, 2025, including those penalties whose associated violation predated January 17, 2025" (16 CFR 1.98(d), read 23 October 2026). [15]

In our reading, section 5(m)(1)(A) is the penalty path for trade regulation rules, and it turns on knowledge. The rule's preamble says civil penalties reach violators "with actual knowledge or knowledge fairly implied on the basis of objective circumstances that such act is unfair or deceptive and is prohibited by such rule" (89 FR 68034, at 68037, footnote 49). [13] The same footnote says "any entity or person who violates such a rule (irrespective of the state of knowledge) is liable for any injury caused to consumers." [13]

The FTC gave a reason for the rule that operators should read plainly: "Without an efficient way to seek civil penalties, bad actors have little fear of being penalized for using fraud and deception in connection with reviews and endorsements" (89 FR at 68037). [13] On amounts, the preamble said "The maximum civil penalty is currently $51,744 per violation, but courts must take into account the statutory factors set forth in section 5(m)(1)(C) of the FTC Act and may impose much lower per-violation penalties," and that "courts will also decide how to calculate the number of violations" (89 FR at 68048). [13] The table has since been adjusted to $53,088. [15]

Our judgment: for a research peptide store, the review rule and the FDA exposure point the same way. A review program that produces fewer health statements and treats every rating the same is safer under both.

Can you remove reviews without breaking FTC rules?

Yes, in our reading of the FTC's consumer review rule, if your withholding criteria are applied equally to all reviews regardless of sentiment; confirm your rule with counsel. [8] The rule makes it a violation to misrepresent the reviews a store displays as representative when reviews are being suppressed "based upon their ratings or their negative sentiment." [8]

The same section says a review is not suppressed on that basis when it is withheld under "criteria for withholding reviews that are applied equally to all reviews submitted without regard to sentiment" (16 CFR 465.7(b)). [8] It lists examples. A review may be withheld when it contains trade secrets or other confidential information; defamatory, harassing, abusive, obscene, vulgar or sexually explicit content; "The personal information or likeness of another individual"; discriminatory content; or "Content that is clearly false or misleading." [8] It may also be withheld when the seller "reasonably believes the review is fake," or when the review is "wholly unrelated" to the products or services offered. [8]

The FTC said in the preamble that "There are numerous legitimate reasons for suppressing consumer reviews," and that it was "not expanding the rule to address other types of review suppression not based on ratings or negative sentiment" (89 FR at 68064). [13] Our reading: the rule targets suppression by rating or sentiment, so a content rule outside the listed examples is possible if it is applied without regard to sentiment.

In practice, a rule that withholds every review describing personal use of a product sold for research would, in our reading, have to remove a glowing five star review and a one star review alike, because the rule turns on whether withholding is based on rating or sentiment. [8] Whether your specific rule fits the FTC's criteria is a question for your lawyer. That is our judgment of how the two sources fit together, not a ruling. For affiliate and influencer programs, see the affiliate and testimonial compliance playbook.

Do payment reviewers read review apps too?

Two practitioners in an October 2026 Shopify Community thread say payment reviewers do read review apps, and Stripe's written policy names deceptive and fake testimonials in its prohibited list. [9][10]

In that thread, which asked what payment reviewers flag, a Shopify Partner wrote that "most payment reviewers also scan content added by third-party apps, subscription tools, loyalty platforms, and even customer review apps." The thread's author, who offers a free check that "reads your store the way a reviewer would," replied that reviews were "the one I'd worry about most." In the same reply, the author wrote that a customer's claim on a supplement page "reads as a claim on your page to a reviewer, even though you didn't write it." [9] Those are two practitioner views, not a processor's written policy.

The written policy is more direct. Stripe's Restricted Businesses page has a section headed "Prohibited Businesses" that says "You must not use Stripe's services for any illegal activities or for the businesses or product types listed below." That list includes "Businesses that make outrageous claims, use deceptive testimonials, use high-pressure upselling, or use fake testimonials (with or without a written contract)" (Stripe, Restricted Businesses, read 8 October 2026). [10]

Our reading: the Stripe line is about testimonials, not about review widgets as such, and it does not say how reviewers inspect a store. It does mean that a testimonial a reviewer judges deceptive is named in a processor's own prohibited list. If you already depend on a high risk processor, see what payment processor you can use to sell peptides and the merchant account underwriting checklist. If an account is already on hold, start with what to do in the first 72 hours.

Does Google care how your store handles reviews?

Yes, for review rich results: Google's review snippet guidelines set rules on who controls the reviews, what the page must show, and how incentives are disclosed. These are Google's search eligibility rules, not law, but they decide whether your star ratings can appear in search results (Google Search Central, Review snippet structured data, last updated 8 September 2026). [18]

Three rules on that page bear on a peptide store. [18]

1. Self serving reviews. "If the entity that's being reviewed controls the reviews about itself, their pages that use LocalBusiness or any other type of Organization structured data are ineligible for star review feature." Google's example includes reviews shown through "an embedded third-party widget." Product is listed separately among the supported types.

2. The markup must match the page. "Make sure the review content you mark up are readily available to users from the marked-up page. It must be immediately obvious to users that the page has review content."

3. No fake or undisclosed incentivized reviews. Google says "Don't include fake or undisclosed incentivized reviews on your page or in your structured data markup," and its examples include reviews written in exchange for a benefit "(such as money, discounts, vouchers, or free products)" that do not disclose it. It also says "Don't aggregate reviews or ratings from other websites."

Our reading, which is judgment: if your theme or review app writes review text into the page code that the visible page does not show, that breaks Google's second rule. It also leaves text a regulator or payment reviewer can read in the page source. The same structured data check below serves all three audiences.

Where does customer text show up on a peptide store?

We count nine places where customer text reaches a store, drawn from the warning letters above and from common store setups. The star widget under the product photo is only the first:

1. Product page review widgets. The obvious one, and the one FDA labeled by name in its 2025 letter. [4]

2. Review pages and verified review hubs. A standalone page of testimonials, especially one your own copy links to. [3]

3. Q&A widgets. Customers ask how others used a product, and other customers answer. The answers display on your page.

4. Photo and video reviews. Captions and on screen text count as text.

5. Imported reviews. Apps that pull reviews from marketplaces, Google or social profiles put outside text on your domain. Google separately says not to aggregate reviews from other websites. [18]

6. Blog posts and articles. A post that quotes or links a customer's experience is customer text on your site. FDA cited a blog article in the CBDFX letter that linked to a testimonial. [3]

7. Package inserts and brochures. FDA cited a testimonial in a brochure enclosed with shipped products in the Let's Talk Health letter. [2]

8. Social accounts that send buyers to the store. The CBDFX and Hydroxie letters both note social accounts that direct consumers to the seller's website. [3][4] Comments you feature or repost there are, in our view, the same kind of text.

9. Structured data. Themes and apps can write text into the page's code for search engines, where buyers never see it but anyone reading the page source can. In a September 2026 Shopify Community thread, one reply said most themes and SEO apps write a product data block (JSON-LD) with its own description, and "That text isn't on the visible page." [11] Our suggestion: check whether your review app writes review text into that code too.

Two more channels deserve a note even though no letter we read quoted them. Review request emails and post purchase pages shape what customers write. If your request asks customers how a product worked for them, in our view you are inviting the content you then have to moderate. Our recommended first step: open three product pages with every app switched on, view the page source, and search it for review text, before a reviewer does.

How do you set up a review policy for a research peptide store?

Our working setup for a review policy has ten steps: decide whether you need product reviews, scope the request, remove sentiment incentives, write the moderation rule, hold reviews for approval, handle insiders, turn off imports, check the page code, keep a moderation log, and recheck after every change. It is not a legal standard; have counsel review it for your business.

1. Decide whether you need product reviews at all. Many research suppliers show lot documentation, test reports and shipping reviews instead. In our view, a store review about delivery speed and packaging carries a different risk from a product review.

2. If you keep reviews, scope the request. Ask about order accuracy, packaging, documentation and delivery. Do not ask about results. Send the same request to every purchaser, which matches the "generalized solicitations to purchasers" language in 16 CFR 465.2(d). [8]

3. Remove any incentive tied to sentiment. In our reading, a discount for a review is a disclosure question; a discount for a positive review is a 465.4 question. The rule bars incentives "conditioned expressly or by implication on" a particular sentiment. [8] If you offer anything for a review, disclose it on the review, as Google also requires. [18]

4. Write the moderation rule down before you publish anything. Name what is withheld (personal use, statements about effects in people, other people's personal information, abusive content, fake or unrelated reviews) and apply it to every rating from one to five stars. [8]

5. Hold reviews for approval. Auto publish puts text on your page before anyone reads it, and the FTC described automatic publishing of only four and five star reviews as suppression. [13] Remember that FDA described approved reviews as ones the company "reviewed and selected." [2] Our working assumption: once you approve a review, treat it as your choice.

6. Handle insiders. Founders, managers, staff, contractors and their relatives either do not review your products or disclose the relationship clearly on the review. [7][8]

7. Turn off imports and syndication from marketplaces and social profiles unless every imported review passes the same rule. Do not forward only favorable reviews to other sites. [7]

8. Check the code, not just the page. View the page source and confirm what your theme and apps write into structured data. [11][18] Remove review or product text you would not show on the page.

9. Keep a moderation log. Record each withheld review, its star rating, the rule it broke, and the date. If a processor, platform or regulator asks, the log shows the rule was applied evenly across ratings.

10. Recheck after every app install, theme change or payment application. New apps add new places for customer text, and the Endorsement Guides describe monitoring as part of the advertiser's job, not a one time step. [7]

Copy this: a review policy and a moderation log

Below is our working review policy for a research peptide store, written from the steps above. It is a template, not a legal standard: fill in the brackets and have counsel review it before you publish it. The test it is built to pass is the one in the FTC's rule: withholding criteria "applied equally to all reviews submitted without regard to sentiment." [8]

Our review policy. We invite every customer to review their order: accuracy, packaging, documentation and delivery. We publish reviews of every star rating, from one to five, that follow this policy.

We do not publish a review, whatever its rating, that: (1) describes personal use of a product or statements about effects in people or animals; (2) contains another person's personal information or abusive language; (3) is fake, comes from someone who did not order from us, or is unrelated to our products or service; (4) comes from our staff, contractors or their relatives without a clear disclosure on the review.

We read every review before it appears. We offer nothing in exchange for a review of a particular rating or sentiment. Questions about a withheld review: [contact address].

Publish it where your review form and your policies page can link to it. Then keep the log. One row per withheld review is enough:

In our reading, the rating column is the part a reviewer will look at: it shows that a five star review describing personal use was withheld under the same rule as a one star review. [8][13]

What you should have when you finish

You are done when you can show all three of these, today, to a payment reviewer or to counsel:

1. The surface list. Every place customer text appears on your store, from the nine above, including what the page source and structured data carry. Our test: you opened the source of three product pages and searched it for review text.

2. The published policy. Your version of the template above is live, linked from the review form, and every new review is held for approval before it appears.

3. The log. Every review you withheld since the policy went live has a row with its star rating and the rule it broke.

If one of the three is missing, that item is your next task. Rerun the audit checklist below after every new app, theme change or payment application.

Customer review audit checklist

Our working checklist, built from the setup above. It is a practice, not a legal standard.

• ☐ Every page that displays customer text is listed, including Q&A, photo reviews, review hubs and blog posts.
• ☐ No page links to reviews as proof of something the product copy does not say.
• ☐ Package inserts, cards and brochures carry no customer quotes.
• ☐ Social accounts that link to the store carry no pinned or reposted customer claims.
• ☐ Review request emails ask only about order, packaging, documentation and delivery, and go to every purchaser.
• ☐ No incentive depends on a positive review, and any incentive is disclosed on the review.
• ☐ A written moderation rule exists and is applied to positive and negative reviews alike.
• ☐ Reviews are held for approval, not published automatically.
• ☐ Insider reviews are either absent or clearly disclosed.
• ☐ Imported and syndicated reviews are off, or pass the same rule.
• ☐ Page source and structured data carry no review text that the visible page would not show.
• ☐ A moderation log records every withheld review, its rating and the reason.
• ☐ The checklist is rerun after each new app, theme change or payment application.

Frequently Asked Questions

Can FDA use customer reviews as evidence against a seller?

Yes. FDA has quoted customer reviews or testimonials from sellers' own websites as evidence of intended use in warning letters, including in 2019, 2022 and 2025. Its regulation says intended use can be shown by advertising matter and written statements by the responsible persons or their representatives, and its 2021 rule says it may look to "any relevant source of evidence."

Did the 2026 peptide warning letters cite customer reviews?

No. We found no quoted customer reviews in the NuScience Peptides and Peptide Partners letters dated August 24, 2026; both cite evidence from the sellers' websites and labeling. Both letters also say they are not an all inclusive list of violations.

Does a "for research use only" disclaimer cover reviews on the same page?

Not in the letters we read. FDA found drug intended use from website evidence despite labeling that limited the products to research use in its 2026 peptide letters. In a 2022 letter, it quoted testimonials from a reviews page that the seller linked to right after saying it could not make claims. The FTC's Endorsement Guides also describe a testimonial disclaimer as likely ineffective in a parallel example.

Will FDA always send a warning letter before taking action?

No. FDA's Regulatory Procedures Manual says FDA "is under no legal obligation to warn individuals or firms" before enforcement action, except in a few defined areas, and that firms "should not assume" they will get a warning letter first.

Is it legal to delete negative reviews?

Not by rating or sentiment, in our reading, when the reviews you display are presented as representative: the FTC's rule treats that as a violation; confirm your policy with counsel. Withholding reviews under criteria applied equally to all reviews, regardless of sentiment, is not treated as suppression.

How much can an FTC review rule violation cost?

The FTC's table sets the maximum civil penalty under section 5(m)(1)(A) at $53,088 per violation for penalties assessed after January 17, 2025. The FTC has said courts must weigh statutory factors and may impose much lower amounts.

Do payment processors check customer reviews?

Two practitioners say yes, and Stripe's written policy names deceptive and fake testimonials among its prohibited businesses. No processor policy we read names review widgets as such.

Do review apps affect Google star ratings?

They can. Google says a business that controls the reviews about itself is ineligible for star review features on LocalBusiness or Organization pages, including reviews shown through an embedded widget, and that marked up review content must be visible on the page.

Sources

1. U.S. Electronic Code of Federal Regulations, 21 CFR 201.128, Meaning of "intended uses". Read 8 October 2026.

2. U.S. Food and Drug Administration, Warning Letter to Let's Talk Health, Inc., 576771, 6 August 2019. Read 23 October 2026.

3. U.S. Food and Drug Administration, Warning Letter to Newhere Inc dba CBDFX, 629243, 16 November 2022. Read 23 October 2026.

4. U.S. Food and Drug Administration, Warning Letter to Hydroxie, LLC, MARCS-CMS 709661, 25 June 2025. Read 23 October 2026.

5. U.S. Food and Drug Administration, Warning Letter to NuScience Peptides LLC, 733652, 24 August 2026, including footnote 1. Read 8 October 2026.

6. U.S. Food and Drug Administration, Warning Letter to Peptide Partners LLC, 735063, 24 August 2026, including footnote 1. Read 8 October 2026.

7. Federal Trade Commission, 16 CFR Part 255, Guides Concerning the Use of Endorsements and Testimonials in Advertising, sections 255.0(a) and (b) and Example 1, 255.1(a), (b), (d) and (f), 255.2(a), (b), (d), (e)(1)(ii), (e)(2) and (e)(4)(vii), and 255.5 Example 8. Read 23 October 2026.

8. Federal Trade Commission, 16 CFR Part 465, Rule on the Use of Consumer Reviews and Testimonials, sections 465.1(d) and (m), 465.2, 465.4, 465.5, 465.6, 465.7 and 465.8. Read 23 October 2026.

9. Shopify Community, thread 692748 on what a payment reviewer would flag, opening post and replies, October 2026. Read 23 October 2026.

10. Stripe, Restricted Businesses, section "Prohibited Businesses." Read 8 October 2026.

11. Shopify Community, thread 686293, reply 7, September 2026. Read 23 October 2026.

12. U.S. Food and Drug Administration, Regulations Regarding "Intended Uses," final rule, 86 FR 41383 (2 August 2021), FR Doc. 2021-15980, pages 41386, 41388, 41399 and 41401. Read 23 October 2026.

13. Federal Trade Commission, Trade Regulation Rule on the Use of Consumer Reviews and Testimonials, final rule, 89 FR 68034 (22 August 2024), FR Doc. 2024-18519, pages 68037 (including footnote 49), 68048, 68052 (including footnote 252), 68064 and 68065 (including footnote 436). Read 23 October 2026.

14. U.S. Food and Drug Administration, Regulatory Procedures Manual, Chapter 4, Advisory Actions, MAN-000007, Revision 12, July 2024, section 4-1-1, pages 3 to 4. Read 23 October 2026.

15. U.S. Electronic Code of Federal Regulations, 16 CFR 1.98, Adjustment of civil monetary penalty amounts, paragraph (d). Read 23 October 2026.

16. Legal Information Institute, Cornell Law School, 21 U.S.C. 321, Definitions, paragraph (g)(1). Read 8 October 2026.

17. Legal Information Institute, Cornell Law School, 15 U.S.C. 52, Dissemination of false advertisements, paragraph (a), and 15 U.S.C. 55, Additional definitions, paragraph (c). Read 8 October 2026.

18. Google Search Central, Review snippet (Review, AggregateRating) structured data, guidelines sections. Last updated 8 September 2026; read 23 October 2026.

Educational and legal disclaimer

This article is general education about business operations for research peptide stores. It is not legal, regulatory or medical advice, and it describes no use of any product in people or animals. Warning letters describe the facts of each recipient's case. Quotations from regulations, rules and letters are reproduced for reference; read the full source before relying on any of them. Obtain qualified advice for your specific business before changing how you collect, moderate or display customer reviews.